Previous Close | 137.20 |
Open | 138.36 |
Bid | 133.81 x 100 |
Ask | 134.04 x 100 |
Day's Range | 133.53 - 138.36 |
52 Week Range | 83.75 - 161.00 |
Volume | |
Avg. Volume | 333,446 |
Market Cap | 7.586B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -9.56 |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.29 |
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript May 4, 2024 Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all […]
Ascendis Pharma ( NASDAQ:ASND ) First Quarter 2024 Results Key Financial Results Revenue: €95.9m (up 186% from 1Q...
— Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for adults with hypoparathyroidism. If approved, U.S. launch planned in Q3 — TransCon CNP (navepegritide) pivotal ApproaCH Trial on track for topline results in Q4 2024 — SKYTROFA® Q1 revenue more than doubled year-over-year to €65 million; Q1 operating expenses